These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30423811)

  • 1. NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.
    Hsu CM; Lin PM; Lin HC; Tsai YT; Tsai MS; Li SH; Wu CY; Yang YH; Lin SF; Yang MY
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30423811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
    Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
    Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
    Molecules; 2020 May; 25(10):. PubMed ID: 32466169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
    Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells.
    Yu Y; Yu X; Ma J; Tong Y; Yao J
    Int J Oncol; 2016 Jul; 49(1):285-93. PubMed ID: 27176231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
    Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A
    Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
    Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
    Liu TJ; Koul D; LaFortune T; Tiao N; Shen RJ; Maira SM; Garcia-Echevrria C; Yung WK
    Mol Cancer Ther; 2009 Aug; 8(8):2204-10. PubMed ID: 19671762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
    Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
    Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
    Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
    Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
    Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
    Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.